British pharmaceutical giant GSK Plc (NYSE:GSK) shares rose on Wednesday after reporting second-quarter results that surpassed analyst expectations and led the company to raise its full-year 2025 ...

Madrigal will study SYH2086 in combination with Rezdiffra for metabolic dysfunction-associated steatohepatitis, aiming for clinical trials in early 2026.

GSK tops Q2 estimates with growth in vaccines and specialty drugs, raises 2025 forecast amid progress in major late-stage pipeline assets.

GSK has concluded the acquisition of efimosfermin alfa, an investigational therapeutic for serious liver disease (SLD), from Boston Pharmaceuticals in a $2bn deal.

Efimosfermin is a phase III-ready investigational treatment for steatotic liver disease (SLD), specifically targeting metabolic dysfunction-associated steatohepatitis (MASH) and alcohol-related liver ...

Efimosfermin is described as a phase III-ready, investigational specialty medicine intended for the treatment and prevention of progression of steatotic liver disease (SLD), including metabolic ...

Efimosfermin is a phase III-ready investigational treatment for steatotic liver disease (SLD), specifically targeting metabolic dysfunction-associated steatohepatitis (MASH) and alcohol-related ...

Efimosfermin is a novel, once-monthly fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH ...